Follow us on twitter

Clinical aspects of heart failure in individuals with diabetes – published online 24/07/2019

Figure from Bowes paper

Christa D. Bowes, Lillian F. Lien, Javed Butler

Cardiovascular outcome (CVO) trials with novel glucose-lowering therapies have provided us with a deeper understanding of the risks and benefits of these agents with respect to cardiovascular outcomes. In turn, CVO trials have allowed individualisation of therapy for patients with diabetes. Since individuals with diabetes are at a higher risk of developing heart failure (HF) and, subsequent to HF development, have much worse prognosis, it is important to consider the issues concerning HF risk and management in these individuals. In this issue, Bowes et al (https://doi.org/10.1007/s00125-019-4958-2) summarise available data on the impact of various glucose-lowering therapies on the risks of developing HF and their role in the prevention of incident HF.  They state that these data will provide clinicians with further insights to help optimise the management of patients with diabetes with and without HF. The figure from this review is available as a downloadable slide.

All News
Top